Digital ulcerations in anti-MDA5 dermatomyositis: Complete resolution following treatment with cyclophosphamide.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): Kim Y;Kim Y; Sykes AJ; Sykes AJ; Tugnet N; Tugnet N; Cheng H; Cheng H
  • Source:
    The Australasian journal of dermatology [Australas J Dermatol] 2020 May; Vol. 61 (2), pp. e251-e252. Date of Electronic Publication: 2019 Dec 23.
  • Publication Type:
    Case Reports; Letter
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Wiley-Blackwell Country of Publication: Australia NLM ID: 0135232 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1440-0960 (Electronic) Linking ISSN: 00048380 NLM ISO Abbreviation: Australas J Dermatol Subsets: MEDLINE
    • Publication Information:
      Publication: New South Wales : Wiley-Blackwell
      Original Publication: [Sydney] Australasian College of Dermatologists.
    • Subject Terms:
      Cyclophosphamide/*therapeutic use ; Dermatomyositis/*drug therapy ; Hand Dermatoses/*drug therapy ; Immunosuppressive Agents/*therapeutic use ; Interferon-Induced Helicase, IFIH1/*immunology; Aged ; Dermatomyositis/etiology ; Dermatomyositis/pathology ; Female ; Hand Dermatoses/etiology ; Hand Dermatoses/pathology ; Humans
    • References:
      Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011; 65: 25-34.
      Tsuji H, Nakashima R, Hosono Y, Imura Y, Yagita M, Yoshifuji H, et al. A Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol. 2019. [Epub ahead of print]. https://doi.org/10.1002/art.41105.
      Combalia A, Giavedoni P, Tamez L, Grau-Junyent JM, Mascaro JM Jr. Bosentan for cutaneous ulcers in anti-MDA5 dermatomyositis. JAMA Dermatol. 2018; 154: 371-3.
      Collantes-Rodriguez C, Jimenez-Gallo D, Ossorio-Garcia L, Villegas-Romero I, Linares-Barrios M. Image Gallery: Cutaneous ulcers in anti-MDA5 dermatomyositis successfully treated with sildenafil. Br. J. Dermatol. 2019. [Epub ahead of print]. https://doi.org/10.1111/bjd.18376.
      Charrow A, Vleugels RA. Cutaneous ulcerations in anti-MDA5 dermatomyositis. N. Engl. J. Med. 2019; 381: 465.
    • Accession Number:
      0 (Immunosuppressive Agents)
      8N3DW7272P (Cyclophosphamide)
      EC 3.6.1.- (IFIH1 protein, human)
      EC 3.6.4.13 (Interferon-Induced Helicase, IFIH1)
    • Publication Date:
      Date Created: 20191224 Date Completed: 20210329 Latest Revision: 20210329
    • Publication Date:
      20240829
    • Accession Number:
      10.1111/ajd.13220
    • Accession Number:
      31869443